Literature DB >> 1687595

A novel bradykinin antagonist with improved properties.

B Lammek1, Y X Wang, I Gavras, H Gavras.   

Abstract

Acylation of the N-terminus of [D-Arg0, Hyp3, Thi5,8, D-Phe7] bradykinin with 1-adamantanecarboxylic acid results in an analogue with enhanced potency of at least 33-fold. The new antagonist has potential as a pharmacological tool in the investigation of the role of endogenous bradykinin in cardiovascular regulation.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1687595     DOI： 10.1111/j.2042-7158.1991.tb03205.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN： 0022-3573            Impact factor:   3.765


  4 in total

Review 1.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

2.  Bradykinin-induced collapse of rat pheochromocytoma (PC12) cell growth cones: a role for tyrosine kinase activity.

Authors:  B Schindelholz; B F Reber
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

3.  Novel Bradykinin Analogues Modified in the N-Terminal Part of the Molecule with a Variety of Acyl Substituents.

Authors:  Małgorzata Sleszyńska; Tomasz H Wierzba; Krzysztof Malinowski; Tereza Tůmová; Bernard Lammek; Jiřina Slaninová; Adam Prahl
Journal:  Int J Pept Res Ther       Date:  2012-01-03       Impact factor: 1.931

4.  Design, synthesis and biological activity of new neurohypophyseal hormones analogues conformationally restricted in the N-terminal part of the molecule. Highly potent OT receptor antagonists.

Authors:  Anna Kwiatkowska; Monika Ptach; Lenka Borovičková; Jiřina Slaninová; Bernard Lammek; Adam Prahl
Journal:  Amino Acids       Date:  2011-10-29       Impact factor: 3.520
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.